An investigation on mantle cell lymphoma (MCL) cells showed that compared with everolimus (an mTOR inhibitor) or NVP-BKM120 (a PI3K inhibitor), BEZ235 could be more potent in suppressing the PI3K/Akt/mTOR pathway. Here, MTOR is linked to mantle cell lymphoma.